Department of Pharmacology and Experimental Therapeutics

Amit K. Tiwari, Ph.D.

Photo of Dr. Tiwari 

Assistant Professor
Department of Pharmacology and Experimental Therapeutics

Phone: 419.383.1913
Frederic and Mary Wolfe Center 282F


2011-2013 Postdoctoral Research Associate, Mount Sinai School of Medicine, NY
2008-2011 PhD, Pharmaceutical Sciences, Pharmacology, St. John's University, NY
2006-2008 MS, Pharmaceutical Sciences, Pharmacology, St. John's University, NY
2001-2005 BS Pharmacy, RamEesh Institute, U.P.T.U. University

Cancer Pharmacology & Systems Therapeutics Laboratory

Tiwari lab 2017

Research Interest

Dr. Tiwari’s long-term goal is to develop safe and effective chemotherapy. His current efforts are directed in the area of:

1.  Drug resistance: Understand the factors associated with chemotherapy failure i.e development of drug resistance, tumor aggressiveness and metastasis, drug-drug interaction and develop strategies to overcome these factors. Major areas of focus are:

    • Multidrug resistance (MDR) due to efflux ABC transporters: particularly understanding the overlapping/redundant functions of transporters in drug disposition
    • Targeting embryogenic signaling pathways (Wnt/b-catenin) and EMT signaling pathways
    • Drug-drug interactions (including Herbal-drug; Cosmetic-drug interactions), other pharmacokinetic challenges

2.  Anticancer drug discovery: Design, synthesis and rationally optimize novel and more effective anticancer agents. Efforts are directed towards

    • Isolation to optimization of more active compounds from semi-synthetic to natural sources (algae, herbs, plants)
    • Define multi-targeted pharmacodynamics mechanism

3.  Novel mechanisms: Define and develop non-apoptotic cell-death mechanisms inducing probes: particularly those that induce dysregulated macropinocytosis and macroautophagy and necroptosis. 

Selected Awards and honors

  • Global Research Engagement Award, RIPER/Govt. of Andhra P, India, 2017
  • Learner Engagement Award, University of Toledo, Ohio, 2016
  • Outstanding scientist -Excellence in Innovation Research Award, RGPV, India, 2016
  • ASM-LINK Undergraduate Research Initiative Fellowship Award, NSF/ASM, 2015
  • Travel award, ABRCMS conference, Seattle, Washington, 2014 and 2015
  • Top citation Award from FEBS journal, 2013
  • Top citation Award from Biochemical Pharmacology, 2011

Selected Publications (out of 62)

Total citation: 1900+
Index (h:19; i-10: 23) 

  1. Amawi H, Karthikeyan C, Pathak R, Hussein NA, Christmann R, Robey R, Ashby CR, Jr., Trivedi P, Malhotra A, Tiwari AK. Thienopyrimidine derivatives exert their anticancer efficacy via apoptosis induction, oxidative stress and mitotic catastrophe. European Journal of Medicinal Chemistry, Accepted July 2017 (IF~4.5)
  2. Amawi H, Hussein NA, Karthikeyan C, Manivannan E, Wisner A, Williams FE, Samuel T, Trivedi P, Ashby CR, Jr., Tiwari AK. HM015k, a novel silybin derivative, multi-targets metastatic ovarian cancer cells and is safe in zebrafish toxicity studies. Frontiers in Pharmacology, Accepted July 2017 (IF~4.4)
  3. Karthikeyan C, Jharia P, Waikar DK, Nusbaum AC, Amawi H, Kirwen EM, Christman R, Arudra SKC, Meijer L, Tiwari AK and Trivedi P. N-(1H-pyrazol-3-yl)quinazolin-4-amines as a Novel Class of Casein kinase 1 δ/ε Inhibitors: Synthesis, Biological Evaluation and Molecular Modeling Studies. Bioorg Med Chem Lett. 2017 Jun 15;27(12):2663-2667. doi: 10.1016/j.bmcl.2017.04.080.  (Appeared on the cover)
  4. Balch C, Ramapuram JB and Tiwari AK. The epigenomics of embryonic signaling pathways in chemo-resistant colon cancer. Front Pharmacol. 2017 May 19;8:267. doi: 10.3389/fphar.2017.00267 (IF~4.4)
  5. Manivannan E, Amawi H, Hussein N, Karthikeyan C,  Fetcenko AC, Narayana Moorthy NSH , Trivedi P and Tiwari AK. Design and discovery of novel silybin analogs as antiproliferative compounds using a ring disjunctive - based, natural product lead optimization approach. Eur J Med Chem. 2017 Jun 16;133:365-378. doi: 10.1016/j.ejmech.2017.03.033. (IF~4.5)
  6. Hussein N, Amawi H, Karthikeyan C, Hall FS, Mittal, R, Trivedi P, Ashby CR and Tiwari AK. The dopamine D3 receptor antagonists PG01037, NGB2904, SB277011A, and U99194 reverse ABCG2 transporter-mediated drug resistance in cancer cell lines. Cancer Lett. 2017 Mar 18;396:167-180. doi: 10.1016/j.canlet.2017.03.015. PMID: 28323029 (IF~6.2)
  7. Amawi H, Ashby C, Tiwari AK. Cancer chemoprevention through dietary flavonoids: Whats limiting? Chin J Cancer. 2017 Jun 19;36(1):50. doi: 10.1186/s40880-017-0217-4. (IF~4.1)
  8. Kirwen EM, Batra T, Karthikeyan C, Deora GS, Vathore V, Mulakayalae C, Mulakayala N, Nusbaum AC, Joel Chena, Amawi H, McIntosh K, Sahabjada, Arantes V, Shivnath N, Chaurasia D, Sharma N, Md Arshad, Trivedi P and Tiwari AK. 2,3-Diaryl-3H-imidazo[4,5-b]pyridine derivatives as potential anticancer & anti-inflammatory agents.Acta Pharmaceutica Sinica B, 2017 Jan;7(1):73-79. doi: 10.1016/j.apsb.2016.05.003. PMID: 28119811
  9. Koduru SV, Tiwari AK, and Ravnic DJ. A Comprehensive NGS Data Analysis of Differentially Regulated miRNAs, piRNAs, lncRNAs and sn/snoRNAs in Triple Negative Breast Cancer. J Cancer. 2017Feb 11;8(4):578-596. doi: 10.7150/jca.17633. PMID: 28367238
  10. Koduru SV, Tiwari AK, Hazard SW, Mahajan M, Ravnic DJ. Comprehensive analysis of non-coding small RNAs in human colorectal cancer. J Genomics. 2017 Feb 28;5:16-31. doi: 10.7150/jgen.18856. PMID: 28348640
  11. McIntosh K, Balch C and Tiwari AK#.  Tackling multidrug resistance mediated by efflux transporters in tumor initiating cells.  Expert Opin Drug Metab Toxicol. 2016 Jun;12(6):633-44. doi: 10.1080/17425255.2016.1179280. PMID: 27116192
  12. Hussain S, Sulaiman A, Balch C, Chauhan H, Alhadidi Q and Tiwari AK#. Natural polyphenols in cancer chemoresistance. Nutrition and Cancer, 2016 Aug-Sep;68(6):879-91. doi: 10.1080/01635581.2016.1192201. PMID: 27366999
  13. Karthikeyan C, Malla R, Ashby CR Jr, Amawi H, Abbott KL, Moore J, Chen J, Balch C, Lee C, Flannery PC, Trivedi P, Faridi J, Pondugula SR, and Tiwari AK#. Pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinolines: Novel compounds that reverse ABCG2-mediated resistance in cancer cells. Cancer Lett. 2016 Mar 21. pii: S0304-3835(16)30180-X. doi: 10.1016/j.canlet.2016.03.030. PMID: 27012188 (IF~6.2)
  14. Narayanan NK, Kunimasa K, Miller G, Tiwari AK and Narayanan B. Antitumor activity of melinjo (Gnetum gnemon L.) seed extract in human and murine tumor models in vitro and in a colon 26 tumor-bearing mouse model in vivo. Cancer Medicine, 2015 Nov;4(11):1767-80. doi: 10.1002/cam4.520. PMID: 26408414
  15. Malla R, Wang Y, Chan W, Tiwari AK, Faridi JS. Genetic ablation of PRAS40 improves glucose homeostasis via linking the AKT and mTOR pathways. Biochem Pharmacol. 2015 Apr 27. pii: S0006-2952(15)00239-7. doi: 10.1016/j.bcp.2015.04.016.
  16. Malla R, Ashby CR, Narayanan N, Narayanan B, Faridi JS, and Tiwari AK#. Proline-rich AKT substrate of 40-kDa (PRAS40) in the pathophysiology of cancer: Biochemical Biophysical Research Communications, 2015, Jul 31;463(3):161-6. doi: 10.1016/j.bbrc.2015.05.041. PMID: 26003731
  17. Pondugula SR, Ferniany G, Ashraf F, Abbott KL, Smith BF, Coleman ES, Mansour M, Bird RC, Smith AN, Karthikeyan C, Trivedi P, Tiwari AK. Stearidonic acid, a plant-based dietary fatty acid, enhances the chemosensitivity of canine lymphoid tumor cells. Biochemical Biophysical Research Communications, 2015 May 15;460(4):1002-7. doi: 10.1016/j.bbrc.2015.03.141. PMID: 25847597
  18. Balaji NV, Ramani MV, Viana AG, Sanglard LP, White J, Mulabagal V, Lee C, Gana TJ, Egiebor NO, Subbaraju GV and Tiwari AK#. Design, Synthesis and In Vitro Cell-based Evaluation of the Anti-cancer Activities of Curcumin and Hispolon Analogs: Bioorg Med Chem. 2015 May 1;23(9):2148-58. doi: 10.1016/j.bmc.2015.03.002. PMID: 25842364
  19. Narayanan NK, Tiwari AK, Kunimasa K, Ashby CR, Narayanan B. Potential Role of Natural Dietary Compounds in the Modulation of Metabolomic Fingerprints of Cancer. Metabolomics , 2014, 5: e131. doi:10.4172/2153-0769.1000e131
  20. Chandrabose K, Lee C, Moore J, Mittal R, Suswam EA, Abott KL, Pondugula SR, Manne U, Trivedi P and Tiwari AK#. Novel Pyrimido[1 ,2 :1,5]-pyrazolo[3,4-b]quinolines derivative circumvents multi drug resistance and produces potent apoptosis in colon cancer cells. Bioorg Med Chem. 2015 Feb 1;23(3):602-11. doi: 10.1016/j.bmc.2014.11.043. PMID: 25537531
  21. Chen JJ, Sodani K, Xiao ZJ, Tiwari AK, Patel A, Yang DH, Chen SD and Chen ZS. BBA, a synthetic derivative of 23-hydroxybutulinic acid, reverses multidrug resistance by inhibiting the efflux activity of MRP7 (ABCC10). PLoS One. 2013 Sep 17;8(9):e74573. doi: 10.1371/journal.pone.0074573.
  22. Tiwari AK# and Chen ZS. Repurposing PDE5 inhibitors as a chemoadjuvants. (June 25th, 2013, Frontiers in Pharmacology)
  23. Patel A, Tiwari AK, Chufan EE, Sodani K, Anreddy N, Singh S, Ambudkar SV, Stephani R and Chen ZS. PD17384, human VEGFR inhibitor, reverses ABCB1 mediated drug resistance in cancer cells. (May 15th, 2013, Cancer Chemo and Pharmacology) PMID: 23673445
  24. Tiwari AK, Zhang R and Gallo JM. Overlapping functions of ABC transporters in topotecan disposition as determined in gene knockout mouse models. (online first, May 1, 2013 Mol Cancer Ther) PMID: 23635651
  25. Tiwari AK, Sodani K, Dai CL, Abuznait AH, Singh S, Xiao ZJ, Vispute S, Patel P, Talele TT, Fu LW, Kaddoumi A, Gallo JM, Chen ZS. Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, andABCC10-multidrug resistance xenograft models. Cancer Lett. 2012 Oct 9. PMID: 23063650
  26. Kuang YH, Patel J, Wu CP, Sodani K, Dai CL, Tiwari AK, Lee J, Fu LW, Ambudkar SV, Korlipara V, Chen ZS.  OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance. Biochem Pharmacol, 2012 Sep 15;84(6):766-74. PMID: 22750060
  27. Chen JJ, Sun YL, Tiwari AK, Xiao ZJ, Sodani K, Vispute SG, Yang DH, Chen SD and Chen ZS. PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of MRP7 (ABCC10) transporter. Cancer Sci. 2012 May 11. doi: 10.1111/j.1349-7006.2012.02328.x. PMID: 22578167
  28. Li T, Yang Y, Cheng C, Tiwari AK, Sodani K, Zhao Y, Chen ZS, . N-biphenyl (terphenyl)-2,2-dichloroacet-amide analogues as anti-cancer drugs: design, synthesis and biological evaluation. Bioorg Med Chem Lett. 2012 doi: 10.1016/j.bmcl. 2012.07.057. PMID: 23067553
  29. Sodani K, Tiwari AK, Dai CL, Patel A, Chen ZS. GW583340 and GW2974, Human EGFR and HER-2 inhibitors, reverse ABCB1- and ABCG2-mediated drug resistance. Biochem Pharmacol. 2012 Jun 15;83(12):1613-22. PMID: 22414725 (IF~5)
  30. Peng XX, Tiwari AK, Wu HC and Chen ZS. Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myeloid leukemia cells. Chin J Cancer. 2012 Feb;31(2):110-8. PMID: 22098951 (IF~4.1)
  31. Chen ZS and Tiwari AK. Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and human genetic diseases. FEBS J. 2011 Sep;278(18):3226-45. Epub 2011 Aug 1. PMID: 21740521 Note: Top citation award 2011-2013)
  32. Shi Z, Tiwari AK, Patel A, Fu LW. Chen ZS. Roles of sildenafil in enhancing drug sensitivity in cancer. Cancer Res, 2011 Jun 1;71(11):3735-8. PMID: 21610107 (IF~9.3)
  33. Ding PR, Tiwari AK, Ohnuma S, Lee JWKK, An X, Dai CL, Lu Q, Singh S, Talele TT, Ambudkar SV, Chen ZS. The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein. Submitted to Plos One, 2011 Apr 28;6(4):e19329. PMID: 21552528
  34. Shi Z, Tiwari AK, Shukla S, Robey RW, Singh S, Kim IW, Bates SE, Peng XX, Abraham I, Ambudkar SV, Talele TT, Fu LW, Chen ZS. Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. Cancer Res, 2011 Apr 15;71(8):3029-41. PMID: 21402712 (IF~9.3)
  35. Tiwari AK, Sodani K, Dai CL, Ashby C, Chen ZS. Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy. Curr Pharm Biotechnol. 2011 Apr 1;12(4):570-94.  PMID: 21118094 (Note: 2nd most cited article in Curr Pharm Biotechnol)
  36. Mi YJ, Liang YJ, Huang HB, Zhao HY, Wu CP, Wang F, Tao LY, Zhang CZ, Dai CL, Tiwari AK, Ma XX, To KKW, Ambudkar SV, Chen ZS, and Fu LW. Apatinib (YN968D1) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette Transporters. Cancer Res 2010 Oct 15;70(20):7981-91. 2010 Sep 28. PMID: 20876799 ((IF~9.3)
  37. An X*, Tiwari AK*, Sun Y, Ding PR, Ashby CR, and Chen ZS. BCR-ABL tyrosine kinase inhibitors in the treatment of philadelphia chromosome positive chronic myeloid leukemia: a review. Leuk Res. 2010 Oct;34(10):1255-68. PMID: 20537386 (*Joint-First Author) (Note: Top 10 most cited article in leukemia research)
  38. Kuang YH, Shen T, Chen X, Sodani K, Hopper-Borge E, Tiwari AK, Lee JW, Fu LW and Chen ZS Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. Biochem Pharmacol 2010 Jan 15;79(2):154-61. Epub 2009 Aug 29. PMID: 19720054 20;4(10):e7520. PMID: 19841739(IF~5)
  39. Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR, Jr., Chen X and Chen ZS. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol 2009 Jul 15;78(2):153-61. Epub 2009 Apr 11. PMID: 19427995 (IF~5)
  40. Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, Chen ZS, Tong XZ and Fu LW. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Cancer Lett 2009 Jun 28;279(1):74-83. Epub 2009 Feb 18. PMID: 19232821 (IF~6.2)
  41. Shi Z, Tiwari AK, Shukla S, Robey RW, Kim IW, Parmar S, Bates SE, Si QS, Goldblatt CS, Abraham I, Fu LW, Ambudkar SV and Chen ZS. Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol 2009 Mar 1;77(5):781-93. Epub 2008 Nov 18. PMID: 19059384 (IF~5)
  42. Dai CL*, Tiwari AK*, Wu CP, Su XD, Wang SR, Liu DG, Ashby CR, Jr., Huang Y, Robey RW, Liang YJ, Chen LM, Shi CJ, Ambudkar SV, Chen ZS and Fu LW. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res 2008 Oct 1;68(19):7905-14 PMID: 18829547 (*Joint-First Author). (IF~9.3)

Book Chapters

  1. Shi Z*, Tiwari AK*, Ashby CR, Fu LW and Chen ZS. Anticancer role of Phospodiesterase 5 inhibitors. The Research and Biology of Cancer I. ISBN: 978-1-477554-999. (*Joint-First Author).
  2. Tiwari AK#, Yang DH, and Chen ZS. Molecular mechanisms of methotrexate resistance. Nova Science Publishers, Inc. ISBN – 978-1-62100-596-4, 2012
  3. Mittal R, Agrawal A, Tourne M, Koduru SV, Viana AG, Reddy G, and Tiwari AK#. Nanoparticle-Based Therapeutics to Circumvent Cancer Chemoresistance. 2013. Recent Developments in Biotechnology. Studium Press LLC, USA (in press), 2014.
Last Updated: 7/27/17